Schreiner MediPharm in cooperation with Ypsomed, has developed an NFC-Label that is applied to the YpsoMate autoinjector. Stored information about the medication is transmitted to its electronic add-on – the SmartPilot, and is recorded via the autoinjector and logged by the SmartPilot. The resulting connected device enhances the safety of patients and assists them in the self-administration of medicines to better comply with prescribed therapies.
           
YpsoMate is an autoinjector for self-medication of a wide range of pharmaceutical substances in a various therapeutic areas. To turn this injection platform into a smart device, Ypsomed developed the SmartPilot – a reusable add-on with embedded sensor technology. The autoinjector is pushed into the SmartPilot and is automatically recognized due to the NFC-Label applied to the injection aid. The information about the medication stored on the NFC chip is transmitted via the SmartPilot to a related smartphone app via Bluetooth connection.
           
The technology behind this connected device is the interlinking of diverse sensors and the label with an integrated NFC chip, which Schreiner MediPharm adapted for YpsoMate. The NFC chip identifies and authenticates the medicine and checks its expiration date.

According to the prescribed therapy, the patient can be guided in real time through the injection process by means of the SmartPilot sensors, and feedback on the correct administration of the medicine can be transmitted.
           
“The integration of NFC technology, which has to ensure reliable reading, in a very small space posed the primary challenge in this label development. Subsequent ease of processing was another specified objective,” said Arne Rehm, product manager RFID/NFC Solutions at Schreiner MediPharm.
           
“The cooperation between Ypsomed and Schreiner MediPharm yielded an innovative and complete solution for pharmaceutical manufacturers, who are now able to provide patients with the SmartPilot, a valuable tool supporting them in self-medication efforts,” said Andreas Schneider, Innovation & Business Development Manager at Ypsomed.
More info: www.schreiner-medipharm.com